Evidence map›Paper›PMID 41083028›Full record

ArticleInternational journal of radiation oncology, biology, physics2026

A Mechanistic Model of Brain Necrosis Progression Based on Vascular Heterogeneity.

Nicolò Cogno, Keyur D Shah, Felix Ehret, Chris Beekman, Heiko Enderling, Robert J Dawson, Wesley E Bolch, Helen A Shih, Harald Paganetti, Ibrahim Chamseddine

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.Clinical and translational radiation oncology · 2027
    Review
  2. Article
  3. RN-DFrontiers in artificial intelligence · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nicolò CognoDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Keyur D ShahDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia.
Felix EhretDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Chris BeekmanDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Heiko EnderlingDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Robert J DawsonMedical Physics Program, College of Medicine, University of Florida, Gainesville, Florida; J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida.
Wesley E BolchMedical Physics Program, College of Medicine, University of Florida, Gainesville, Florida; J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida.
Helen A ShihDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Harald PaganettiDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Ibrahim ChamseddineDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: ichamseddine@mgh.harvard.edu.

Funding

Project 3: Enhanced Sensitivity of Tumors to Proton Beam Therapy: Mechanisms and Biomarkers.P01CA261669 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GROSSHANS, DAVID R · 2021 to 2025
$14.0M
Development and application of whole-body patient-specific computational mesh phantoms for organ dosimetry and second primary cancer risk quantification following external beam radiotherapyF31CA288051 · NCI · UNIVERSITY OF FLORIDA · PI Robert Joseph Dawson · 2024 to 2026
$133k
NCI NIH HHS F31 CA288051NCI NIH HHS P01 CA261669
6 · The paper itself

Abstract

purposeBrain radionecrosis (RN) is a significant late toxicity of radiation therapy, yet its progression remains challenging to predict because of patient-specific factors. This study develops a mechanistic model to simulate RN expansion focusing on vascular heterogeneity. METHODS AND MATERIALS: A 3-dimensional cellular automaton (CA) model was developed to simulate RN progression, based on the assumption that vascular heterogeneity drives its spatial dynamics. Patient-specific vasculature maps were generated by registering a synthetic brain phantom to magnetic resonance imaging-derived segmentations. Microvessel length density (L

resultsThe model successfully predicted RN expansion patterns, achieving area under the curve values of 0.87 to 0.95 in validation cases. Simulated necrotic regions exhibited anisotropic expansion influenced by local vascular density, supporting the vascular hypothesis. Patient-specific posterior distributions for progression rate reflected wide interpatient variability, whereas the necrotic neighboring effect had a narrower range. The model consistently identified high-risk voxels, with predicted necrotic regions overlapping observed RN in FU imaging.

conclusionsThis study presents a mechanistic model that integrates vascular heterogeneity to predict RN progression, providing interpretable, patient-specific risk maps. It extends RN evolution modeling beyond dose-based metrics, potentially aiding in refining treatment planning and adaptive FU strategies to minimize radiation-induced toxicity.

Indexed as

BrainBrain NeoplasmsRadiation InjuriesBayes TheoremDisease ProgressionHumansMagnetic Resonance ImagingMicrovesselsMonte Carlo MethodNecrosisPhantoms, ImagingROC Curve

Identifiers

PMID41083028
PMCPMC12688031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.